Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 10;13(Suppl 7):111-22.
doi: 10.4137/CIN.S16346. eCollection 2014.

Managing Multi-center Flow Cytometry Data for Immune Monitoring

Affiliations

Managing Multi-center Flow Cytometry Data for Immune Monitoring

Scott White et al. Cancer Inform. .

Abstract

With the recent results of promising cancer vaccines and immunotherapy1-5, immune monitoring has become increasingly relevant for measuring treatment-induced effects on T cells, and an essential tool for shedding light on the mechanisms responsible for a successful treatment. Flow cytometry is the canonical multi-parameter assay for the fine characterization of single cells in solution, and is ubiquitously used in pre-clinical tumor immunology and in cancer immunotherapy trials. Current state-of-the-art polychromatic flow cytometry involves multi-step, multi-reagent assays followed by sample acquisition on sophisticated instruments capable of capturing up to 20 parameters per cell at a rate of tens of thousands of cells per second. Given the complexity of flow cytometry assays, reproducibility is a major concern, especially for multi-center studies. A promising approach for improving reproducibility is the use of automated analysis borrowing from statistics, machine learning and information visualization21-23, as these methods directly address the subjectivity, operator-dependence, labor-intensive and low fidelity of manual analysis. However, it is quite time-consuming to investigate and test new automated analysis techniques on large data sets without some centralized information management system. For large-scale automated analysis to be practical, the presence of consistent and high-quality data linked to the raw FCS files is indispensable. In particular, the use of machine-readable standard vocabularies to characterize channel metadata is essential when constructing analytic pipelines to avoid errors in processing, analysis and interpretation of results. For automation, this high-quality metadata needs to be programmatically accessible, implying the need for a consistent Application Programming Interface (API). In this manuscript, we propose that upfront time spent normalizing flow cytometry data to conform to carefully designed data models enables automated analysis, potentially saving time in the long run. The ReFlow informatics framework was developed to address these data management challenges.

Keywords: Flow cytometry; REST API; automated analysis; data management; data provenance; laboratory informatics; metadata; reproducible analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of ReFlow hardware components.
Figure 2
Figure 2
Overview of ReFlow software components.
Figure 3
Figure 3
Data schema for ReFlow showing the mapping of table names to flow cytometry domain concepts. Arrows indicate foreign key relationships between database tables.
Figure 4
Figure 4
Data schema detail for ReFlow showing the relationships that define the Panel Template and Site Panel domain concepts.
Figure 5
Figure 5
Data schema for ReFlow showing the process request models.
Figure 6
Figure 6
ReFlow data schema illustrating clustering models used to store process request results.
Figure 7
Figure 7
ReFlow REST API URL schema illustrating various component labels.
Figure 8
Figure 8
Sample upload snapshot.
Figure 9
Figure 9
Panel creation snapshot.
Figure 10
Figure 10
ReFlow screen shot demonstrating the visualization of clustering data. A detailed explanation of the viewing options is presented in the main text.

References

    1. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–9. - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. - PMC - PubMed
    1. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838–47. - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. - PMC - PubMed
    1. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18:1254–61. - PubMed

LinkOut - more resources